Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Bromocriptine Mesylate

FDA-approved product (capsule, oral), marketed as Bromocriptine Mesylate, Cycloset, Parlodel.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Bromocriptine Mesylate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Acromegaly
  • Adenoma
  • Hyperprolactinemia
  • Hypogonadism
  • Infertility
  • Parkinson disease
  • Type 2 diabetes mellitus

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Prolactine inhibitors; Dopamine agonists
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA55.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli52.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae48.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis53.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Bromocriptine Mesylate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.5 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.0 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.7 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Bromocriptine Mesylate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Randomized Single-blind Placebo Controlled Comparative Trial of Pramipexole and Bromocriptine in Parkinson's Disease

    NCT00240409 · start 2003-07

    Registered record
    Registry ID
    NCT00240409
    Conditions
    Parkinson Disease
    Interventions
    Pramipexole; Bromocriptine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2003-07
    Completion
    2004-08
    Enrolment
    208

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson Disease
    InterventionPramipexole; Bromocriptine
    PhasePhase 3
    Registry statusCompleted

  • Safety and Efficacy of Pramipexole and Bromocriptine Combined With L-dopa in Parkinson's Disease

    NCT02172573 · start 1999-04

    Registered record
    Registry ID
    NCT02172573
    Conditions
    Parkinson Disease
    Interventions
    Pramipexole; Bromocriptine; Placebo pramipexole; Placebo bromocriptine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1999-04
    Completion
    Not recorded
    Enrolment
    315

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson Disease
    InterventionPramipexole; Bromocriptine; Placebo pramipexole; Placebo bromocriptine
    PhasePhase 3
    Registry statusCompleted

  • Ophthalmologic Safety of Long Term Treatment With Pramipexole Compared to Bromocriptine or Other Dopamine Agonists in Patients With Parkinson's Disease

    NCT02233023 · start 1998-06

    Registered record
    Registry ID
    NCT02233023
    Conditions
    Parkinson Disease
    Interventions
    Pramipexole; Bromocriptine and other dopamine agonists
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    1998-06
    Completion
    Not recorded
    Enrolment
    705

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson Disease
    InterventionPramipexole; Bromocriptine and other dopamine agonists
    PhasePhase 4
    Registry statusCompleted

  • Pilot Study of the Effect of Baclofen and Bromocriptine on Luteinizing Hormone Secretion in Pubertal Children

    NCT00004793 · start 1995-06

    Registered record
    Registry ID
    NCT00004793
    Conditions
    Growth Disorders
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    1995-06
    Completion
    Not recorded
    Enrolment
    4

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGrowth Disorders
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Phase II Study of Stereotypes and Mental Retardation: Neurobiological Basis

    NCT00004300

    Registered record
    Registry ID
    NCT00004300
    Conditions
    Stereotyped Behavior; Mental Retardation
    Interventions
    bromocriptine; sertraline hydrochloride
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Suspended
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStereotyped Behavior; Mental Retardation
    Interventionbromocriptine; sertraline hydrochloride
    PhasePhase 2
    Registry statusSuspended